Harrow, Inc. (HROW)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$38.54+0.73%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Harrow aims to grow revenue to about $357 million in 2026. It targets adjusted EBITDA near $90 million. The company is focused on increasing Q2 revenue to $71 million or more. Recent acquisitions and debt raise show efforts to strengthen the business.
Revenue fell sharply in Q1 and missed expectations. The company cut guidance and faces operating losses. Achieving full-year targets requires a strong rebound that is uncertain. Debt issuance adds financial risk.
The market expects about 55% revenue growth in the next year. Our fair value near $18.75 reflects this growth but the recent guidance cut and Q1 miss raise doubts about hitting targets.
Breaks if: Adjusted EBITDA falls below $80M in FY26
Deliver full-year 2026 Adjusted EBITDA in the range of $80 million to $100 million as reiterated across multiple quarters.
Stated as a priority in 3 of last 3 quarters. Management reiterated full-year 2026 Adjusted EBITDA guidance of $80 million to $100 million consistently. Adjusted EBITDA was negative $1.2 million in 2026-Q2 and negative $13.9 million for the first six months, indicating the company is not yet delivering but maintaining focus on this target.
“Reiterated full-year 2026 guidance of $80 million to $100 million in Adjusted EBITDA”
“Full-year 2026 Adjusted EBITDA guidance of $80 million to $100 million”
“Full-year 2026 Adjusted EBITDA guidance of $80 million to $100 million”
Breaks if: Debt service issues or refinancing problems arise
Breaks if: Q2 revenue falls below $71M
Achieve second quarter 2026 revenue in the range of $71 million to $81 million as guided.
Stated in 2 of last 2 quarters. Management guided Q2 2026 revenue between $71 million and $81 million. Actual revenue reported was $70.7 million, slightly below the low end of guidance. The trajectory shows near achievement but slightly missing the guided range.
“Quarterly revenue of $70.7 million, an increase of 60% sequentially”
“Second Quarter revenue expected between $71 million and $81 million”
Breaks if: Revenue falls below $350M in FY26
Deliver full-year 2026 revenue in the range of $350 million to $365 million as reiterated across multiple quarters.
Stated as a priority in 3 of last 3 quarters. Management reiterated full-year 2026 revenue guidance of $350 million to $365 million consistently. Quarterly revenue grew from $44.2 million in 2026-Q1 to $70.7 million in 2026-Q2, showing sequential growth. The trajectory is delivering toward the annual revenue guidance.
“Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue”
“Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million”
“Full-year 2026 revenue guidance of $350 million to $365 million”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. HROW is currently navigating a challenging landscape with volatile management and loss-making status, but recent financial performance has been strong, keeping the thesis intact.
The market seems to have priced in a low expectations gap, indicating that HROW is viewed as justified despite its premium valuation compared to peers. The current valuation reflects a durable premium, suggesting that investors expect continued performance in line with recent results.
Management is focused on achieving revenue guidance and expanding its product offerings, which could support growth. However, there is a near-term risk of missing earnings expectations, as the company has had erratic performance in recent quarters.
The future performance of HROW hinges on external factors such as guidance from management in upcoming calls and the performance of key sector peers. Additionally, macroeconomic conditions, particularly job market trends, could impact HROW's trajectory.
Over the next 1 to 3 years, HROW's outlook will depend on its ability to execute on its growth strategies while navigating market volatility. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company aims to increase Q2 2026 revenue to $71M-$81M, indicating strong product momentum. However, the latest earnings miss raises concerns about performance. Additionally, Viatris selling Tyrvaya challenges growth potential for HROW's dry eye franchise.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.